Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV PrEP Implementation in South Korean MSM
NCT04583267Unknown
- Sponsor
- Yonsei University
- Start
- Aug 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Yonsei University. Primary endpoint: Rate of adherence to PrEP with TDF/FTC at 3 months. Status: unknown.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04583267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583267.